Kintara sets Sept 20 vote on TuHURA merger; REM-001 enrolled 4 of 10 patients; warns of bankruptcy without deal

TuHURA Biosciences, Inc./NV

Special Meeting on Sept 20, 2024 to vote on TuHURA merger; existing holders get 5.45% of combined co. plus CVRs.
REM-001 CMBC study: 4 of 10 target patients enrolled as of Sept 10, 2024; no safety issues; Phase 3 dose assessment ongoing.
Without the merger, Kintara states it likely lacks adequate resources to continue operations and may seek bankruptcy protection.
Majority of REM-001 costs covered by $2.0M SBIR grant from NIH; potential to offer much needed treatment for CMBC.
CVRs allow additional shares if ≥10 patients enrolled and complete 8-week follow-up by Dec 31, 2025.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.